Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response

Public Health Reports

Volumn 127, Issue 1, 2012, Pages 23-37

  Thompson, Kimberly M ^a   Wallace, Gregory S ^b   Tebbens, Radboud J Duintjer ^a   Smith, Philip J ^b   Barskey, Albert E ^b   Pallansch, Mark A ^b   Gallagher, Kathleen M ^b   Alexander, James P ^b   Armstrong, Gregory L ^b   Cochi, Stephen L ^b   Wassilak, Steven G F ^b  

^a Kid Risk Inc   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; CHILD; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; EPIDEMIC; HEALTH CARE AVAILABILITY; HEALTH SURVEY; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; NEWBORN; POLIOMYELITIS; POLIOMYELITIS VIRUS; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; UNITED STATES;

EID: 84863393750     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335491212700104     Document Type: Article

References (61)

1. Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298:2155-63.
2. Certification of poliomyelitis eradication-the Americas, 1994. MMWR Morb Mortal Wkly Rep 1994;43(39):720-2.
3. Follow-up on poliomyelitis-United States, Canada, Netherlands, 1979. MMWR Morb Mortal Wkly Rep 1997;46(50):1195-9.
4. Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal 2006;26:1423-40.
5. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR Morb Mortal Wkly Rep 1997;46(8):183]. MMWR Recomm Rep 1997;46(RR-3):1-25.
6. Impact of the sequential IPV/OPV schedule on vaccination coverage levels-United States, 1997. MMWR Morb Mortal Wkly Rep 1998;47(47):1017-9.
7. Prevots DR, Burr RK, Sutter RW, Murphy TV; Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-5):1-22.
8. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants [published erratum appears in MMWR Morb Mortal Wkly Rep 2003;52(16):379]. MMWR Morb Mortal Wkly Rep 2003;52(10):203-4.
9. Imported vaccine-associated paralytic poliomyelitis-United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55(4):97-9.
10. Alexander JP, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009;199:391-7.
11. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep 2008;57(39):1079-80.
12. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep 2008;57(39):1078-9.
13. DeVries AS, Harper J, Murray A, Lexau C, Bahta L, ChristensenJ, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 2011;364:2316-23.
14. Jenkins PC, Modlin JF. Decision analysis in planning for a polio outbreak in the United States. Pediatrics 2006;118:611-8.
15. Alexander L, Birkhead G, Guerra F, Helms C, Hinman A, Katz S, et al. Ensuring preparedness for potential poliomyelitis outbreaks: recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP). Arch Pediatr Adolesc Med 2004;158:1106-12.
16. Update: measles-United States, January-July 2008. MMWR Morb Mortal Wkly Rep 2008;57(33):893-6.
17. Dayan GH, Ortega-Sanchez IR, LeBaron CW, Quinlisk MP; Iowa Measles Response Team. The cost of containing one case of measles: the economic impact on the public health infrastructure-Iowa, 2004. Pediatrics 2005;116:e1-4.
18. Parker AA, Staggs W, Dayan GH, Ortega-Sanchez IR, Rota PA, LoweL, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med 2006;355:447-55.
19. Chen SY, Anderson S, Kutty PK, Lugo F, McDonald M, Rota PA, etal. Health care-associated measles outbreak in the United States after an importation: challenges and economic impact. J Infect Dis 2011;203:1517-25.
20. Onorato IM, Modlin JF, McBean MA, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6.
21. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol 2005;162:358-72.
22. Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM. Optimal vaccine stockpile design for an eradicated disease: application to polio. Vaccine 2010;28:4312-27.
23. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med 2008;10:190.
24. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal 2006;26:1541-56.
25. Salmon DA, Sotir M, Pan WK, Berg JL, Omer SB, Stokley S, et al. Parental vaccine refusal in Wisconsin: a case control study. WMJ 2009;108:17-23.
26. Salmon DA, Moulton LH, Omer SB, DeHart MP, Stokley S, Halsey NA. Factors associated with refusal of childhood vaccines among parents of school-aged children: a case-control study. Arch Pediatr Adolesc Med 2005;159:470-6.
27. Smith PJ, Singleton JA. Vaccination coverage estimates for selected counties: achievement of Healthy People 2010 goals and association with indices of access to care, economic conditions, and demographic composition. Public Health Rep 2008;123:155-72.
28. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993;15:265-302.
29. Prevots DR, Pascual FB, Angellili ML, Brayden R, Irigoyen M, Larussa P, et al. Population immunity to polioviruses among preschool children from four urban underserved low income communities, United States, 1997-2001. Pediatr Infect Dis J 2004;23:1130-6.
30. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA 1996;275:1639-45.
31. Faden H, Duffy L, Sun M, Shuff C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J Infect Dis 1993;168:452-4.
32. Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005;191:990-9.
33. Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J Infect Dis 1997;175 Suppl 1:S228-34.
34. Stickle G. Observed and expected poliomyelitis in the United States, 1958-1961. Am J Public Health Nations Health 1964;54:1222-9.
35. Chin TD, Marine WM, Hall EC, Gravelle CR, Speers JF. Poliomyelitis in Des Moines, Iowa, 1959. The influence of Salk vaccination on the epidemic pattern and the spread of the virus in the community. Am J Hyg 1961;74:67-94.
36. Marine WM, Chin TD, Gravelle CR. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg 1962;76:173-95.
37. Gelfand HM, LeBlanc DR, Potash L, Fox JP. Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg 1959;70:312-27.
38. Oostvogel P, van Wijngaarden J, van der Avoort HG, Mulders MN, Conyn-van Spaendonck MA, Rümke H, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet 1994;344:665-70.
39. Young Center for Anabaptist and Pietist Studies at Elizabethtown College. Amish population by state (2008) [cited 2008 May 24]. Available from: URL: http://www2.etown.edu/amishstudies/Population_by_State_2008.asp
40. Smith PJ, Chu SY, Barker LE. Children who have received no vaccines: who are they and where do they live? Pediatrics 2004;114:187-95.
41. Sugerman DE, Barskey AE, Delea MG, Ortega-Sanchez IR, Bi D, Ralston KJ, et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics 2010;125:747-55.
42. National, state, and local area vaccination coverage among children aged 19-35 months-United States, 2007. MMWR Morb Mortal Wkly Rep 2008;57(35):961-6.
43. Centers for Disease Control and Prevention (US). Immunization coverage in the US, 2009 [cited 2010 Mar 24]. Available from: URL: http://www.cdc.gov/vaccines/stats-surv/nis/default.htm#nis
44. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, et al. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Anal 2008;28:855-76.
45. Böttiger M. Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 1990;8:443-5.
46. Glezen WP, Lamb GA, Belden EA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 1966;83:224-37.
47. Glezen PW, McCollough RH, Lamb GA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol 1969;90:146-56.
48. Wehrle PF, Hagen F, Carbonaro O. Transmission of polioviruses. II. Spread of attenuated poliovirus type III in a partially immunized school population. Pediatrics 1961;27:755-61.
49. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 5th ed. Philadelphia: Elsevier, Inc.; 2008. p. 631-85.
50. Public health dispatch: measles epidemic-Majuro Atoll, Republic of the Marshall Islands, July 13-September 13, 2003. MMWR Morb Mortal Wkly Rep 2003;52(37):888-9.
51. Measles outbreak in a boarding school-Pennsylvania, 2003. MMWR Morb Mortal Wkly Rep 2004;53(14):306-9.
52. Import-associated measles outbreak-Indiana, May-June 2005. MMWR Morb Mortal Wkly Rep 2005;54(42):1073-5.
53. Multistate measles outbreak associated with an international youth sporting event-Pennsylvania, Michigan, and Texas, August-September 2007. MMWR Morb Mortal Wkly Rep 2008;57(7):169-73.
54. Outbreak of measles-San Diego, California, January-February 2008. MMWR Morb Mortal Wkly Rep 2008;57(8):203-6.
55. Lack of evidence for wild poliovirus circulation-United States, 1993. MMWR Morb Mortal Wkly Rep 1995;43(51-52):957-9.
56. Alexander JP, Wallace GS, Wassilak SGF; Centers for Disease Control and Prevention (US). Traveler's health: yellow book: chapter 3 infection diseases related to travel: poliomyelitis [cited 2010 Oct 1]. Available from: URL: http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/poliomyelitis.htm
57. Omer SB, Pan WK, Halsey NA, Stokley S, Moulton LH, Navar AM, et al. Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. JAMA 2006;296:1757-63.
58. Omer SB, Salmon DA, Orenstein WA, DeHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccinepreventable diseases. N Engl J Med 2009;360:1081-8.
59. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep 2009;58(30):829-30.
60. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40(RR-10):1-28.
61. Shrestha SS, Wallace GS, Meltzer MI. Modeling the national pediatric vaccine stockpile: supply shortages, health impacts, and cost consequences. Vaccine 2010;28:6318-32.